Project Grant R43HL172285
Award Date
9/23/24
Completion Date
8/31/25
Dollars Obligated
$300K
Federal Agency
National Heart Lung and Blood Institute
Awardee
Mogling Bio Inc. (HUMFJ81ML352)
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Cincinnati, OH 45208, USA
Similar Awards
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $146,876 to the Coriell Institute for Medical Research to develop new methods for expanding functional hematopoietic stem cells (HSCs) from cryopreserved umbilical cord blood (UCB) samples. The project aims to optimize an approach using PPAR-α agonists, which have been shown to significantly expand long-term functional UCB HSCs...
This federal Project Grant award of $735,085.00 was provided by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to Case Western Reserve University to conduct research on "Leveraging HSF1 Attenuation to Transform Clonal Hematopoiesis into Beneficial Hematopoiesis." The research aims to investigate how modulating the heat shock transcription factor 1 (HSF1) can sustain or enhance hematopoietic stem/progenitor cell function and prevent the...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $295,438 to the University of Florida to develop a novel ex vivo expansion platform for human hematopoietic stem cells (HSCs). The goal is to significantly increase the availability of suitable HSC donors for hematopoietic stem cell transplantation and improve post-transplant recovery, which is critical for treating life-threatening blood and bone marrow...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) for $1,000,000 aims to determine whether changing the signaling patterns between skeletal stem cells (SSCs) and hematopoietic stem cells (HSCs) can treat atherosclerotic cardiovascular disease (ASCVD). The research will characterize the effects of SSC aging on the vasculature and test whether targeted reversal of age-related decreases in BMP2 signaling in SSCs can alter ASCVD progression. The award was...
This Project Grant award of $734,607 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) aims to elucidate the key endothelial mechanisms that direct hematopoietic stem cells (HSCs) across the blood vessel wall and into their niche. The research, conducted by Boston Medical Center Corporation, will use high-resolution live cell imaging, structure-function studies, and in vivo proximity-dependent biotinylation in zebrafish to define the endothelial...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $814,209 project grant under the Cardiovascular Diseases Research (CFDA 93.837) program to the Fred Hutchinson Cancer Center in Seattle, Washington. The goal of this 4-year project, starting May 1, 2025, is to develop and evaluate targeted nanoparticles for in vivo hematopoietic stem cell gene therapy to treat genetic blood diseases and disorders. Key objectives include optimizing nanoparticle formulations loaded with gene editing...
This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to the Trustees of Indiana University, Indianapolis provides $792,498 to investigate the regulation of hematopoietic stem cells (HSCs) under low oxygen tension (hypoxia). The research aims to understand the signaling and metabolic alterations in HSCs under hypoxic conditions and explore the potential to manipulate these processes in normoxic conditions to improve HSC...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $802,301 to Weill Medical College of Cornell University to conduct research on controlling the stem cell niche to mitigate the risks of clonal hematopoiesis, a condition that affects over 7 million people in the U.S. and increases their risk for life-shortening diseases. The research aims to define the mechanisms that switch the stem cell niche on and off,...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research investigating the mechanisms linking persistent DNA damage to the upregulation of NLRP12, and the functional links between persistent DNA damage and NLRP12 in aging hematopoiesis. The $1,419,308 award, effective from Sep 17, 2024 to Aug 31, 2025, is being provided to the University of Pittsburgh to conduct this study. The research aims to elucidate a...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $164,460 to the University of California, San Diego (UCSD) to investigate the role of translation fidelity in maintaining hematopoietic stem cell (HSC) function and longevity. The award aims to determine if young adult HSCs have higher translation fidelity compared to progenitor cells and aged HSCs, and whether enhancing translation fidelity can mitigate...